SCIENMAG: Medicine & Health

JUNE 9, 2023

Virginia Tech Intellectual Properties (VTIP) with LINK + LICENSE + LAUNCH’s Proof-of-Concept Program has provided the springboard for faculty to bring their research to market. Over the past four years, the program has funded 24 Virginia Tech research projects. Credit: Photo by Luke Hayes for Virginia Tech.

Research 84

Research Licensing Licensing Marketing 84

Drug Target Review

DECEMBER 9, 2024

Since its launch, AlphaFold has accurately predicted the structure of over 200 million proteins and been used by more than 2 million researchers globally. The second half of the prize was awarded to David Baker, a structural biologist from the University of Washington, for his research in computational protein design.

Engineering 105

Engineering International Drug Development Science 105

Reprocell

SEPTEMBER 19, 2024

The biological license application (BLA) is one of the many requests for marketing approval received by the FDA. Unlike the New Drug Application (NDA) which is usually the go-to submission for chemically synthesized, low molecular weight drugs BLAs grant sponsors the ability to introduce Biologics into interstate commerce.

Licensing 59

Licensing Licensing Regulations FDA 59

BioPharma Drive: Drug Pricing

AUGUST 3, 2023

A treatment licensed from the NIH and in clinical testing for lupus is the startup’s lead program, while its founding “Treg” cell therapy research matures, according to CEO Peter Maag.

Therapies 130

Therapies Licensing Licensing Treatment 130

Crown Bioscience

MAY 2, 2024

Whether you're a researcher, a biotech professional, or someone keen on understanding the nuances of cell line screening, this discussion will provide valuable insights into how Crown Bioscience can support your scientific endeavors.

Licensing 52

Licensing Licensing Research Regulations 52

Perficient: Drug Development

OCTOBER 20, 2023

While it proved to be tricky to find an opening for an infant, we endeavored to compare in-home daycares and licensed facilities. In contrast, the licensed facilities we used maintained extended afternoon hours, providing a tad more flexibility for evening pickups. Luckily, Perficient is very family friendly.

Licensing 52

Licensing Licensing Doctors Regulations 52

National Institute on Drug Abuse: Nora's Blog

JANUARY 3, 2025

A new roadmap for cannabis and cannabis policy research mfleming Fri, 01/03/2025 - 11:38 Nora's Blog January 14, 2025 Image Getty Images/ Fiordaliso The greatly increased availability of cannabis over the last two decades has outpaced our understanding of the public-health impacts of the drug.

Research 78

Research Production Licensing Licensing 78

FDA Law Blog: Biosimilars

FEBRUARY 5, 2024

HP&M has been helping clients navigate the challenges of state licensing regulations for drugs, biologics, medical devices, OTCs, 503B outsourcing facilities, 503A pharmacies, foods, dietary supplements, cannabis, and wholesalers/distributors for many years. Keup has joined the firm to assist attorneys Karla L.

Licensing 45

Licensing Licensing Pharmacy Regulations 45

The Pharma Data

OCTOBER 27, 2021

NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders. About MODAG.

Licensing 52

Licensing Licensing Disease Small Molecule 52

Drug Discovery Today

NOVEMBER 11, 2022

Stockholm, Sweden, November 8, 2022 – Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target.

Licensing 100

Licensing Licensing Drugs Research 100

The Pharma Data

MARCH 9, 2022

Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets.

Licensing 52

Licensing Licensing Therapies Disease 52

LifeSciVC

JULY 17, 2024

We are building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis that originated at Genzyme and then continued at Sanofi, where our founding scientists discovered first-in-class correctors that in preclinical studies directly stabilized the first nucleotide-binding domain (NBD1) of the CFTR protein.

Clinical Research 69

Clinical Research Disease Research Clinical Trials 69

Drug Patent Watch

JULY 13, 2020

Mudawi in the Journal of Pharmaceutical Research International under the terms of the Creative Commons Attribution License.…. This article was originally published by Mohammed M. Alshehri and Mahmoud M. The post Common Drugs with Effective Off-Label Uses appeared first on DrugPatentWatch - Make Better Decisions.

Licensing 94

Licensing Licensing Drugs International 94

Fierce BioTech

JULY 12, 2023

Real-World Data for Cardiovascular Disease Research These days, top-tier biopharma companies are using real-world data (RWD) to power their cardiovascular disease research. With so many sources of data, both in-house and licensed, we know it can be hard to sort through it all and analyze what you need to answer your research questions.

Disease 52

Disease Research Licensing Licensing 52

Broad Institute

JULY 25, 2024

Researchers identify cheap and effective biomarkers for DCIS tumor stage By Tom Ulrich July 25, 2024 Breadcrumb Home Researchers identify cheap and effective biomarkers for DCIS tumor stage New study shows how leveraging unsupervised learning can decode DCIS progression from chromatin images. Paper cited Zhang X et al.

Research 69

Research Disease Treatment Clinical Trials 69

Drug Target Review

MARCH 17, 2025

Donello was most recently Vice President of External Science & Innovation at Allergan/AbbVie, where he led R&D innovation efforts to develop strategic collaborations, in-license clinical-stage assets and evaluate M&A opportunities. He holds an honours Bachelor of Science degree in biology from Indiana University.

Treatment 52

Treatment Licensing Licensing Science 52

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Licensing 52

Licensing Licensing Therapies Science 52

Conversations in Drug Development Trends

OCTOBER 26, 2022

Having worked in psychedelic research since the advent of industry-sponsored trials, Worldwide Clinical Trials has amassed the expertise needed to execute these studies successfully, recently sharing insights in a webinar titled “ Demystifying Complex Operations in Psychedelic Research ,” available on-demand now.

Trials 97

Trials Clinical Trials Licensing Licensing 97

Molecule Blog

AUGUST 19, 2021

TL;DR: This week, the first university biomedical intellectual property (IP) and research project was funded as an NFT (non-fungible token), enabled by a pioneering innovation at Molecule. The IP-NFT enables new fundraising and collaboration strategies for researchers by combining legal and technical frameworks with NFT technology.

Research 52

Research Licensing Licensing Drug Development 52

Drug Target Review

NOVEMBER 28, 2024

In many cases, life sciences organisations are using technologies that were not specifically designed for scientific data, leading to inefficiencies in both research and operations. A new, single, centralised source of truth must be created, with security, governance and compliance as top priorities, serving as a trusted research environment.

Science 59

Science Government Engineering Licensing 59

Predictive Oncology

MARCH 17, 2023

Cancer Research Horizons to incorporate PEDAL into future drug discovery processes to enable drug development on a global scale 11 marketed drugs 2nd largest oncology out-licensor globally 150+ active licenses 160+ new drugs into early-phase clinical trials $647 million revenue from royalties & IP $2.8

Research 52

Research Clinical Trials Licensing Licensing 52

Drug Target Review

NOVEMBER 25, 2024

I went on to complete my MBA and PhD at The Institute of Cancer Research (ICR) in drug development. This suited my personality and constant curiosity more than academic research. This pathway, called the PI3K pathway, had been largely researched and discarded. Believe that you can do it and keep that belief.

Treatment 52

Treatment Small Molecule Clinical Trials Trials 52

Molecule Blog

JANUARY 9, 2023

The future of research is collaborative, digital, and highly autonomous. Research is built on data (and sometimes code) that routinely isn’t shared, affecting our ability to replicate science. Researchers make proposals to the system for projects that contribute to solving the disease. Patents today are not.

Research 52

Research Licensing Licensing Science 52

Predictive Oncology

MARCH 21, 2023

Dominic Pollard of Cancer Research Horizons and Dr. Pamela Bush of Predictive Oncology discuss the potential impact of their collaboration and how it can advance cancer drug development. Click here to view the interview.

Research 52

Research Licensing Licensing Drugs 52

SCIENMAG: Medicine & Health

JULY 20, 2023

Researchers at the University of Illinois Chicago have identified a process by which enzymes can help prevent heart damage in chemotherapy patients. Credit: Image adapted from the research paper. Creative Commons license).

Licensing 74

Licensing Licensing Research 74

Drug Target Review

SEPTEMBER 5, 2024

However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company. I am a pharmacist by training and continued with a PhD in Clinical Pharmacology.

Pharma Companies 111

Pharma Companies Licensing Licensing Disease 111

The Pharma Data

JUNE 14, 2023

Global Head of Research and Early Development for Oncology, Pharmaceuticals Division, Bayer AG. With our oncology strategy, we are dedicated to accelerating the research and development of novel cancer therapies that have the potential to make a meaningful difference in the lives of patients.”

Licensing 40

Licensing Licensing Small Molecule Science 40

The Pharma Data

MAY 2, 2022

– Gilead to License Exclusive Worldwide Rights to the Investigational Candidate DF7001, a 5T4-Targeting NK Cell Engager for Solid Tumors –. – Gilead to Have Options to License Several Additional NK Cell Engager Programs –. Gilead Sciences, Inc.

Licensing 52

Licensing Licensing Research Protein Expression 52

Drug Hunter

JUNE 25, 2023

This edition includes Maze’s glycogen synthase 1 (GYS1) inhibitors that were recently licensed to Sanofi, allosteric androgen receptor (AR) modulators that may be of interest to targeted protein degradation researchers, and brain-penetrant HER2 and ROCK2 inhibitors.

Targeted Protein Degradation 130

Targeted Protein Degradation Computational Chemistry Trials Licensing 130

FDA Law Blog: Biosimilars

JUNE 12, 2024

With input from medical professionals, stakeholder, trade associations, and patient advocacy groups, FDA provided a pathway to market for air-conduction hearing aids without a prescription or the involvement of a licensed professional. But the GAO Report highlights the lack of research on OTC hearing aids thus far.

FDA 111

FDA Regulations Treatment Licensing 111

The Pharma Data

MARCH 25, 2022

Food and Drug Administration (FDA) has extended the review of the supplemental biologics license application (sBLA) for Reblozyl® (luspatercept-aamt) for the treatment of anemia in adults with non-transfusion-dependent (NTD) beta thalassemia to June 27, 2022. Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. in November 2021.

Licensing 52

Licensing Licensing Drugs Treatment 52

Drug Target Review

APRIL 23, 2024

The current limitations of FEP calculations One obstacle which researchers face when deciding to implement relative FEP approaches is that it can only be used for similar ligands, limiting its applicability especially in early stage hit-to-lead. One approach is to use bespoke scheduling strategies such as Adaptive Lambda Scheduling.

Licensing 100

Licensing Licensing Drugs Drug Development 100

DrugBank

AUGUST 15, 2024

Novartis provided the funding and expertise in clinical trial design and regulatory affairs, while the University of Oxford's research team led the development of the gene therapy technology. The relationship between industry and academia is evident in numerous high-level collaborations. In 2022 alone, global sales of Repatha reached $1.28

Drug Development 98

Drug Development Clinical Trials Drugs Therapies 98

Molecule Blog

MARCH 17, 2023

Moving research from concept to market is like conducting a symphony — there are numerous players and stakeholders, each bringing their unique expertise to work in harmony and advance a project. BioDAOs fund and incubate projects during the initial stages of translational research, often through IP-NFTs, even before a company is established.

Engineering 52

Engineering Research Clinical Trials Government 52

DrugBank

NOVEMBER 7, 2023

The healthcare community can license ASHP data for use in new or existing software, databases, or websites in formats specific to organisational needs. DrugBank is honoured to partner with the world’s leading biomedical researchers as they pursue their goal of better medical outcomes.

Pharmacy 105

Pharmacy Community Pharmacies Pharmaceutical Companies Packaging 105

Broad Institute

MAY 14, 2024

His T7 expression technology can be used to make large quantities of nearly any RNA or protein and has been for decades, and continues to be, a mainstay of biomedical research and pharmaceutical production. The motivation for my research is not commercial application. My interest is in basic research." and around the world.

RNA 84

RNA Production Molecular Biology Laboratories 84

Drug Target Review

MARCH 4, 2025

Phenomix Sciences, built on over a decade of clinical research at the Mayo Clinic, is disrupting this outdated approach. The research demonstrated that obesity is not one disease, but many; each of which should be treated with different interventions, says Bagnall. These individuals respond four times better to GLP-1 medications.

Therapies 52

Therapies Treatment Clinical Trials Science 52